Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $2.93M, compared with -$150K a year earlier. Trailing-twelve-month accounts payables was $5.87M. Over 3 fiscal years it compounded at +375.3% a year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $2.93M or moves back toward the trailing-twelve-month quarterly average of $1.47M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.93M+150.1% QoQ
Last fiscal yearDec 2025
$2.79M+144.7% YoY
LTMMar 2026
$5.87M+736.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2050.0%——
1 year+144.7%——
3-year CAGR+375.3%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.79M USD
Year-over-year change
+144.7%

Accounts Payables vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +736.9% is the highest of 10, against a peer median of +3.7%.
  • Over three fiscal years its annual growth of +375.3% compares with a peer median of -3.3%.
LRMR Competitors
Accounts Payables for LRMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$17.22M USD+128.8%—8.0%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$8.3M USD-220.6%+54.2%—
ANNXAnnexon, Inc.LTM Mar 2026$6.67M USD+3.7%——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$5.87M USD+736.9%+375.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$4.34M USD-72.9%+66.1%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$3.03M USD+109.0%-7.1%—
KRROKorro Bio, Inc.LTM Mar 2026$2.56M USD-290.8%—66.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$1.98M USD+327.2%-39.7%—
ALTAltimmune, Inc.LTM Mar 2026$453K USD+116.9%-3.3%1258.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 327.34K CHF——9.2%
ENGNenGene Holdings Inc.LTM Apr 2026$105K USD-108.0%——
Peer median (excluding LRMR) —+3.7%-3.3%37.9%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Depreciation & Amortization326K318K311K318K(1.35M)
Deferred Income Tax00000
Stock-Based Compensation5.47M6.62M7.62M8.8M7M
Change in Working Capital2.75M1.67M(2.51M)6.18M47.1M
Accounts Receivables00000
Inventory00000
Accounts Payables(974K)26K(403K)1.14M2.79M
Other Working Capital3.72M1.64M(2.11M)5.03M44.31M
Other Non-Cash Items(15K)(820K)(1.93M)(5.45M)(281K)
Operating Cash Flow(42.11M)(27.57M)(33.46M)(70.76M)(113.2M)
Capital Expenditures(333K)(100K)(164K)(515K)(91K)
Acquisitions (Net)(24.5K)90.86K000
Purchases of Investments(8.25M)(133.61M)(101.23M)(227.87M)(83.6M)
Sales of Investments32.75M42.75M134.75M143M184M
Other Investing Activities24.5K(90.86K)000
Investing Cash Flow24.17M(90.96M)33.35M(85.39M)100.31M
Debt Repayment00000
Common Stock Issued19.89M75.26M30K161.81M65.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00077K0
Financing Cash Flow19.89M75.26M30K161.88M65.09M
Effect of Forex Changes00000
Net Change in Cash1.95M(43.27M)(76K)5.74M52.19M
Free Cash Flow(42.44M)(27.67M)(33.62M)(71.28M)(113.29M)

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.